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 Abstract:
The current article discusses how momentary assessment may fundamentally contribute to 
identifying environmental risk factors and symptom patterns, as well as provide new 
opportunities for treatment. A new prototype device, the “PsyMate,” was specifically developed 
to implement momentary assessment in clinical practice. It was shown that self-monitoring of 
both positive and negative psychotic symptoms (a) is feasible, (b) provides a much more detailed 
and fine-grained picture of symptoms, and (c) reveals patterns of behavior that may be relevant 
for treatment. Furthermore, the PsyMate could be instrumental for real-time and real-world 
delivery of psychological interventions. With PsyMate, patients can become active partners in 
the therapeutic process, resulting in greater patient ownership and empowerment as well as 
understanding of their symptoms and the environment. 
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Article: 
Introduction 
Psychotic symptoms are natural experiences emerging in the realm of normal daily life, often in 
interaction with contextual features. These contextual features, however, have mainly been 
identified through epidemiological research, resulting in general, global risk factors for 
psychosis,1–3 limiting the applicability for individualized intervention strategies. Momentary 
assessment approaches, on the other hand, using structured diary techniques, such as the 
Experience Sampling Method (ESM)4,5 or Ecological Momentary Assessment,6 have shown 
that both internal and external contextual features may influence the frequency and intensity of 
symptoms as they unfold in daily life.5 The current article will discuss how momentary 
assessment may fundamentally contribute to identifying these personal risk factors and symptom 
patterns as well as provide new opportunities for treatment. 
The PsyMate: A Clinical Momentary Assessment Tool 
Numerous methods and technologies have been employed to collect momentary assessment data 
in daily life including paper and pencil, notebooks, PDAs, mobile telephones, and online 
reporting.7 However, all of these methods suffer from limitations. Therefore, a new prototype 
device, the “PsyMate”, was specifically developed to implement momentary assessment in 
clinical practice (see figure 1). The PsyMate is designed to monitor experiences and behavior in 
daily life by signaling patients and recording and time-stamping their responses. It is small, 
lightweight, has a user-friendly interface and allows for easy and flexible programming, with the 
possibility to respond to the input of the subject. It is easily accessible for participants with 
limited familiarity with technological devices, thus overcoming some of the problems that have 
been reported with PDAs and mobile phones.7 The PsyMate is currently being used in 2 trials on 
depression.8 In the current article, we will focus on its applicability in psychosis. 
 
  
 
Fig. 1. 
The PsyMate Device: When Signaled, Patients Respond to Questions Regarding Thoughts, 
Mood, Symptoms as well as the Context, and Appraisals Thereof. 
 
Can Patients With Psychosis Become Active Partners in Their Symptom Assessment? 
Essential characteristics of psychotic phenomena include frequency of occurrence, variability 
over time, and the interplay with the context in which they are occurring. Despite the clinical 
relevance of these characteristics, very little of this information is available to the clinician or to 
the patient, for that matter. People are generally poor in providing accurate, global, retrospective 
reflections of real-life experiences, and behavior, and this appears to be especially problematic 
for patients with psychosis who experience a loss of reality testing and suffer from cognitive 
impairment. Furthermore, people are not always consciously aware of the patterns of behavior 
and the subtle interplay between experiences and environmental features. 
Similar to advantages in somatic medicine of real-time monitoring of blood pressure9 or plasma 
glucose levels,10 real-time monitoring of psychiatric symptoms may considerably improve the 
understanding of the nature and expression of symptoms as well as actively engage patients in 
this assessment and monitoring process. Clinical studies are already underway for psychiatric 
disorders such as anxiety, eating disorders, or depression7,8,11; however, researchers and 
clinicians alike have yet to explore these opportunities in psychosis. 
Positive Symptoms of Psychosis 
The positive symptoms of psychosis, such as disturbances in the content of thought and in 
sensory perception, tend to be difficult for patients to accurately self-monitor. Patients are often 
unaware of the deviant nature of these experiences; however, items, such as “preoccupation with 
thoughts,” “feeling paranoid,” “feeling controlled,” or “feeling unreal,” capture aspects of mental 
state that are associated with delusions and that patients can accurately report. Similarly, patients 
can provide veridical self-report about the intensity of hallucinations, even when they are not 
aware of the origin of these experiences. 
Studies using ESM have demonstrated that there is considerable variation in the intensity of both 
delusions12,13 and hallucinations14 over periods of minutes and hours. Furthermore, this 
variability in symptom intensity is driven both by internal and external factors. Increases in 
paranoia, eg, were precipitated by a decrease in self-esteem13 (see figure 2), an increase in 
anxiety,13,15 and increased feelings of subjective stress.16External factors have also been 
implicated in the onset of positive symptoms including day-to-day urban exposure,17 social 
context,18 and cannabis use.19 Cannabis use, eg, immediately increased positive affect, whereas 
the increase in hallucinations occurred thereafter. This temporal dissociation between the acute 
rewarding effects and the subsequent toxic influences may explain the vicious circle of 
deleterious use in these patients. 
  
 
Fig. 2. 
The PsyMate May Be Used to Capture Temporal Associations Between Real-Time Variability in 
Internal States (eg, Self-esteem) and in Symptoms (eg, Paranoia). 
 
Negative Symptoms of Psychosis 
Negative symptoms of psychosis reflect deficits in cognitive functioning, experience of pleasure, 
and interest, motivation, and engagement in the world.20,21 These symptoms seem even less 
accessible to real-life self-monitoring because current assessment instruments rely solely on 
observer-rated behavior.20 However, the experiential and behavioral manifestations of negative 
symptoms can be self-monitored by patients in real life. It was shown, eg, that patients with a 
psychotic disorder show increased intensity and variability of negative emotions but a reduced 
intensity of positive emotions.22 This may reflect anhedonia, diminished capacity to experience 
pleasure, or rather result from living a less pleasant life. In a second study, it was shown that 
patients with a psychotic disorder were equally if not more able to experience pleasure when 
something pleasant was happening, only fewer pleasant events were reported (Oorschot M, 
Lataster T, Thewissen V, et al., unpublished data). It was also shown that patients reported 
similar levels of pleasure during activities as control participants but reported less anticipatory 
pleasure from future goal-directed activities.23 
These results represent group comparisons rather than assessing individual risk profiles of 
patients. Yet, these data show that self-monitoring of both positive and negative psychotic 
symptoms (a) is feasible, (b) provides a much more detailed and fine-grained picture of 
symptoms, and (c) reveals patterns of behavior that may be relevant for treatment. Thus, patients 
with psychosis, even during acute phases of the illness, can become active partners in the 
assessment of their symptoms. Furthermore, the fine-grained assessment of symptoms and 
behavior may accelerate and fundamentally broaden the assessment of treatment efficacy, both at 
the individual level as well as in clinical trials. 
 
From Assessment to Treatment in Real Life 
In addition to real-time assessment of symptoms, the PsyMate could be instrumental for real-
time and real-world delivery of psychological interventions. This procedure, referred to as 
Ecological Momentary Intervention,7 can extend therapeutic interventions for patients with 
psychosis beyond the clinical setting. The integration of assessment and treatment in the 
PsyMate allows for an individual-tailored intervention with the possibility of delivering feedback 
that is directly related to symptom intensity or environmental risks. Ecological Momentary 
Intervention for psychiatric problems has primarily been used to supplement other psychological 
treatments such as Cognitive Behavioral Therapy.7 However, it could also be used as a treatment 
in and of itself. So far, almost no real-time applications have been developed for treatment of 
psychosis. We will outline some of the possibilities below. 
Paranoia 
As previously outlined, there is an evidence that the experience and expression of paranoia are 
strongly driven by increased anxiety and decreased self-esteem and is exacerbated/triggered by 
environmental cues. At a metacognitive level, the PsyMate could be used to increase awareness 
of this pattern, eg, through giving patients feedback on these processes at the end of the 
assessment period. Similarly, feedback in real time may aid in inducing behavioral changes; for 
example, when patients become more anxious, real-time feedback could be provided helping 
patients to actively reduce the anxiety, thus reducing the risk that paranoia intensity would 
increase. The PsyMate may also be instrumental in conducting individualized behavioral 
experiments in the context of cognitive behavioral therapy (CBT). Paranoia, eg, often leads to 
safety behaviors to mitigate the perceived threat (eg, avoiding potentially “dangerous” 
situations), thus missing the opportunity to gather disconfirming evidence.24 The PsyMate could 
be used to (a) set up the exercise and to gather real-time information about the behavioral 
experiments and (b) provide detailed information on the real-life outcomes of these tests. 
Hallucinations 
The PsyMate could be used in the treatment of hallucinations as well.25One recent article 
describes an ongoing trial in schizophrenia using mobile technology to provide a brief 
intervention for hallucinations that involves cognitive (eg, “but you mentioned in the past that 
voices are just sounds and can’t really hurt you”) and behavioral (eg, “try not responding to see 
what happens … ”) interventions through text exchange 3 times a day.24 With the PsyMate, a 
more frequent (up to 10 times a day) and more detailed assessment of symptom intensity as well 
as contextual risk profile could be achieved. More importantly, however, the PsyMate could be 
used to provide individual-tailored feedback rather than generic interventions, related to the real-
time presence of the hallucinations, helping patients to challenge for example, beliefs about 
voices’ power and intent25 as they occur in real life. 
Negative Symptoms 
Very few treatments, if any, have proven to be successful for negative symptoms.20 One of the 
central problems underlying negative symptoms seems to be a divide between the experience of 
pleasure and motivation.26 Patients with psychosis report an equal capacity to experience 
pleasure compared with controls. However, experienced pleasantness does not result in increased 
motivation for this activity, resulting in the paradoxical situation that patients do not often 
engage in activities that they actually enjoy. Feedback on this process through real-time 
monitoring of the patterns of behavior may increase insight in and awareness of this divide. 
PsyMate data may also aid in discovering which activities or situations result in increased 
feelings of pleasure. Real-life monitoring may also be used to induce behavioral changes. For 
example, patients could receive real-time support to undertake activities that were previously 
been identified as pleasant. 
In conclusion, the PsyMate offers a device that is not only instrumental in the assessment of 
psychosis but may also provide treatment interventions in real-world settings as well as monitor 
the efficacy of these interventions. With PsyMate, patients can become active partners in the 
therapeutic process, resulting in greater patient ownership and empowerment as well as 
understanding of their symptoms and the environment. This would be entirely congruent with the 
proposed “next generation” of CBT for psychosis where it is argued that more focus is required 
on the interaction of emotions, context, and delusions as well as on the safety behaviors that 
support threat beliefs about persecutors27: PsyMate is ideal to move therapy out of the office and 
into the patient’s day-to-day experience. 
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